Aktieanalys

Elicera Therapeutics: Promising first data from CARMA study - Redeye

{newsItem.title}

Redeye Publicerad: 21 Jan 15:52

Elicera Therapeutics

Redeye gives an initial take on the first clinical results from the CARMA study with ELC-301.

Länk till analysen i sin helhet: https://www.redeye.se/research/1068511/elicera-therapeutics-promising-first-data-from-carma-study?utm_source=finwire&utm_medium=RSS

Nyheter om Elicera Therapeutics

Läses av andra just nu

Om aktien Elicera Therapeutics

Senaste nytt